SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
Recruiting · NCT07710248 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SG301-SC Injection Safety Study in Subjects With Primary ITP Patients | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-09 | NCT07710248 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hangzhou Sumgen Biotech Co., Ltd. | 8 |
22 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.